Accrued interest

No definition available.

Name:	abvcd_AccruedInterest
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Advances bear interest description.

+ References

No definition available.

+ Details

Name:	abvcd_AdvancesBearInterestDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate working capital.

+ References

No definition available.

+ Details

Name:	abvcd_AggregateWorkingcapital
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Investment and equity transfer agreement description.

+ References

No definition available.

+ Details

Name:	abvcd_InvestmentAndEquityTransferAgreementDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	abvcd_OutstandingAdvanceFromRelatedParty
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The value of outstanding services charge.

+ References

No definition available.

+ Details

Name:	abvcd_OutstandingServicesCharge
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	abvcd_RelatedPartiesTransactionsTextualAbstract
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock purchase agreement description.

+ References

No definition available.

+ Details

Name:	abvcd_StockPurchaseAgreementDescription
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870

+ Details

Name:	us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount receivable from related parties classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_DueFromOtherRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DueToRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Name:	us-gaap_InterestExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121576215&loc=SL77919370-209981

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121603689&loc=d3e36975-112693

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918703-209980

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121606570&loc=SL77919784-209982

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_RelatedPartyTransactionDescriptionOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShorttermDebtAverageOutstandingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_DebtInstrumentAxis=abvcd_UnsecuredConvertiblePromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=abvcd_NoteHoldersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_KimhoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abvcd_TypeOfCurrencyAxis=abvcd_NTMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_LbgUsaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteTaiwanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtConversionByUniqueDescriptionAxis=abvcd_ConversionAgreementsOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteBVIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_EverfrontBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abvcd_AgreemnetAxis=abvcd_ConversionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_JIANGSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_LionGeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_DueToshareholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_EuroAsiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_ConsultingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Parties Transactions (Details Textual) - USD ($)													1 Months Ended													9 Months Ended	12 Months Ended
	Jul. 02, 2020	May 08, 2020	Apr. 14, 2020	Oct. 15, 2019	Aug. 02, 2019	Jul. 12, 2019	Jul. 02, 2019	May 12, 2019	Feb. 02, 2019	May 11, 2018	Sep. 25, 2017	Apr. 12, 2017	Oct. 31, 2020	Aug. 31, 2019	Jun. 30, 2019	May 27, 2019	Feb. 27, 2019	Jan. 20, 2019	Dec. 31, 2018	Nov. 30, 2018	Jun. 27, 2018	Jan. 18, 2018	Dec. 31, 2017	Sep. 30, 2017	Jan. 26, 2017	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 08, 2018
Related Parties Transactions (Textual)
Principal amount			$ 124,400
Interest expenses																											$ 405,032	$ 482,014
Loan maturity date			Apr. 13, 2022
Conversion price														$ 7.00
Conversion of debt														$ 4,872,340
Conversion of debt, shares														696,051
Related party transactions, description																													Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $837,726 to 119,675 shares of the Company’s common stock at a conversion price of $7.00 per share.
Outstanding advance balance																											$ 288,445	425,689
Keypoint Note [Member]
Related Parties Transactions (Textual)
Principal amount																					$ 250,000
Interest rate percentage																					8.00%
Note Holders [Member]
Related Parties Transactions (Textual)
Aggregated common shares																											795,735
Employee Stock [Member]
Related Parties Transactions (Textual)
Advances bear interest, description																											The Company had advances from one employee for working capital purpose. The outstanding balance due to this employee amounted to $72,704 as of December 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand.
Kimho [Member]
Related Parties Transactions (Textual)
Related party transactions, description							The Company entered into an agreement with Kimho for consulting service, with such services to begin in September 2019. As of December 31, 2020 and 2019, the outstanding services charge was $0 and $21,500, respectively.
Outstanding advance balance																												21,500
Outstanding services charge																											52,000	21,500
BioFirst [Member]
Related Parties Transactions (Textual)
Principal amount						$ 150,000
Outstanding loan balance																											0	128,683
Accrued interest																											$ 0	8,468
Loan agreement, description																											Bears interest at 1% per month (or equivalent to 12% per annum
Aggregate working capital						21,317
Stock purchase agreement, description											On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.
Outstanding advance balance																											$ 23,647	24,182
Rgene Corporation [Member]
Related Parties Transactions (Textual)
Principal amount																											2,911	36,332
Outstanding loan balance																											31,684	29,194
Accrued interest																											$ 11,227	7,138
Loan agreement, description																											The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019
Asiangene Corporation [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																											$ 0	3,343
Accrued interest																											681	235
Aggregate working capital																											0	$ 24,017
Amount of equivalent																$ 3,560
Interest rate percentage																												0.00%
Outstanding advance balance																												$ 24,017
Asiangene Corporation [Member] \| NT [Member]
Related Parties Transactions (Textual)
Loan agreement, description																The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019.
Aggregate working capital																$ 100,000
BioFirst (Australia) [Member]
Related Parties Transactions (Textual)
Principal amount	$ 321,487					$ 150,000				$ 40,000
Outstanding loan balance																											$ 373,235	40,000
Interest rate percentage	12.00%					12.00%				0.00%																	12.00%
Loan maturity date	Jun. 30, 2021					Jul. 11, 2020
Other receivable from related parties																											$ 123,583	115,946
Advances bear interest, description						The advances bear interest 1% per month
LBG USA, Inc.[Member]
Related Parties Transactions (Textual)
Loan agreement, description																	The advances bear 0% interest rate and are due on demand.
Outstanding advance																			$ 0								$ 675	675	$ 0
BioLite Taiwan [Member]
Related Parties Transactions (Textual)
Loan agreement, description																											The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.
Aggregate working capital																				$ 430,817
Interest rate percentage																				0.00%
Other receivable from related parties																			$ 0										$ 0
Conversion price																														$ 7.00
Conversion of debt					$ 428,099
Conversion of debt, shares					61,157
BioLite Taiwan [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital																				$ 13,295,000
BioFirst [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																											$ 160,871
Aggregate working capital																							$ 625,646		$ 950,000
Interest rate percentage									12.00%														12.00%				12.00%
Loan maturity date									Feb. 01, 2020														May 27, 2020
Conversion price																							$ 7.00
Conversion of debt																							$ 625,646
Conversion of debt, shares																							89,378
Stock purchase agreement, description									On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company’s common stock at a conversion price of $7.00 per share.						Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.
BioFirst [Member] \| Conversion Agreements One [Member]
Related Parties Transactions (Textual)
Interest rate percentage																							0.00%
Stock purchase agreement, description																							On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company’s common stock at a conversion price of $7.00 per share.
BioFirst [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital																							$ 19,430,000
BioLite BVI [Member]
Related Parties Transactions (Textual)
Aggregate working capital												$ 987,134
Interest rate percentage												12.00%
Loan maturity date								May 11, 2020				May 11, 2019
Stock purchase agreement, description								On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company’s common stock at a conversion price of $7.00 per share.
BioLite BVI [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital												$ 30,000,000
Everfront Biotech Inc. [Member]
Related Parties Transactions (Textual)
Investment and equity transfer agreement, description																								Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.
YuanGene [Member]
Related Parties Transactions (Textual)
Aggregate working capital																						$ 50,000					$ 9,205	9,205
Interest rate percentage																						12.00%
Loan maturity date																		Jan. 19, 2020				Jan. 19, 2019
Conversion price					$ 7.00
Conversion of debt					$ 50,000
Conversion of debt, shares					7,143
YuanGene [Member] \| Conversion Agreements [Member]
Related Parties Transactions (Textual)
Aggregate working capital					$ 42,690
Interest rate percentage					0.00%
Conversion price					$ 7.00
Conversion of debt					$ 42,690
Conversion of debt, shares					6,099
Related party transactions, description					On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $42,690 to 6,099 shares of the Company’s common stock at a conversion price of $7.00 per share.
Jiangs [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																											2,488
Accrued interest																											$ 5,947	154
Interest expenses																										$ 0		1
Loan agreement, description																											The advances bear 0% interest rate and are due on demand.
Aggregate working capital																											$ 16,627	$ 40,031
Interest rate percentage																			0.00%							0.00%		1.00%
Related party transactions, description																													Since 2018, the Jiangs have advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.
Lion Gene [Member]
Related Parties Transactions (Textual)
Outstanding loan balance																											0	$ 10,020
Accrued interest																											0	255
Interest expenses																										$ 0	955	255
Lion Gene [Member] \| NT [Member]
Related Parties Transactions (Textual)
Aggregate working capital				$ 300,000
Amount of equivalent				$ 10,020
Due to Shareholders [Member]
Related Parties Transactions (Textual)
Accrued interest																											166,261	284,479
Interest expenses																											21,520	14,910
Outstanding advance balance																											166,261	284,479
Due to Shareholders [Member] \| NT [Member]
Related Parties Transactions (Textual)
Loan agreement, description																													The advances bear interest rate from 12% to 13.6224% per annum.
Amount of equivalent																			$ 160,770										$ 160,770
Euro Asia [Member]
Related Parties Transactions (Textual)
Outstanding advance																												12,000
Outstanding advance balance																											0	12,000
BioLite Japan [Member]
Related Parties Transactions (Textual)
Loan agreement, description		The Company advanced an amount of $150,000 and the advance bear 0% interest rate.
Aggregate working capital		$ 150,000
Outstanding advance																											$ 0	$ 0
Consulting Agreement [Member]
Related Parties Transactions (Textual)
Conversion price																											$ 2.9
Aggregated common shares																											521,887
Keypoint [Member]
Related Parties Transactions (Textual)
Principal amount													$ 1,610
Outstanding loan balance																											$ 1,610
Interest rate percentage													6.50%
Loan maturity date													Oct. 30, 2021